E Coli Peritonitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for e coli peritonitis. 12 active patents protecting 2 drugs from 2+ originators. First major cliff: 2031. Daily refresh.

2
Approved drugs
12
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in E Coli Peritonitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 10 patents Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating e coli peritonitis. Each bar = one year. Y-axis scaled to peak year (7 patents).

1
28
1
30
7
31
1
38
2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Merrem
Meropenem
 Pfizer 10 57 — 2031-08-08
Tobi
tobramycin
 Novartis 2 72 — 2028-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8869794 Tobi method of use 75 2028-09-12
12478606 Merrem method of use 75 2038-01-08
12533342 Merrem method of use 75 2039-05-20
11376237 Merrem method of use 70 2039-04-06
10207066 Tobi method of use 68 2030-11-04
10183034 Merrem method of use 68 2031-08-08
11007206 Merrem method of use 68 2031-08-08
9694025 Merrem method of use 68 2031-08-08
10561675 Merrem method of use 68 2031-08-08
10172874 Merrem formulation 48 2031-08-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8680136 Merrem composition of matter 10 2031-08-29
12171772 Merrem composition of matter 23 2031-08-08
10172874 Merrem formulation 48 2031-08-08
11007206 Merrem method of use 68 2031-08-08
10183034 Merrem method of use 68 2031-08-08
10561675 Merrem method of use 68 2031-08-08
9694025 Merrem method of use 68 2031-08-08
10207066 Tobi method of use 68 2030-11-04
11376237 Merrem method of use 70 2039-04-06
12533342 Merrem method of use 75 2039-05-20

Related